Skip to main content

Table 4 Univariate analysis for overall survival and progression free survival in high-intermediate and high risk IPI patients

From: Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

  Median OS, months HR (95% CI) P-value Median PFS, months HR (95% CI) P-value
Age       
   < 60 years 7.0 0.79 (0.39-1.61) 0.512 2.9 0.50 (0.24-1.01) 0.059
   ≥ 60 years 9.2    9.6   
Gender       
   Male 10.1 1.33 (0.64-2.76) 0.444 8.1 1.07 (0.29-2.29) 0.862
   Female 5.2    3.5   
Performance status       
   0-1 10.1 1.72 (0.79-3.73) 0.168 8.1 1.15 (0.51-2.59) 0.728
   2-4 4.8    3.6   
B symptom       
   Absent 9.2 1.29 (0.62-2.66) 0.490 8.1 1.09 (0.51-2.33) 0.810
   Present 7.0    3.6   
Stage       
   1-2 4.0 0.21(0.02-0.72) 0.147 3.6 0.45 (0.05-3.44) 0.445
   3-4 9.2    8.1   
Extranodal involvement       
   0-1 10.1 1.13 (0.56-2.28) 0.729 14.7 1.27 (0.61-2.67) 0.518
   ≥ 2 8.1    3.9   
Bone marrow involvement       
   Negative 11.9 1.33 (0.66-2.67) 0.414 9.5 1.29 (0.64-2.61) 0.467
   Positive 7.3    7.0   
LDH       
   Normal 9.2 1.51 (0.45-4.97) 0.498 8.1 1.54 (0.46-5.10) 0.474
   Elevated 7.6    7.3   
PIT       
   Group 1-2 16.9 1.35 (0.58-3.14) 0.476 8.1 1.06 (0.45-2.48) 0.883
   Group 3-4 7.6    7.3   
ALC       
   ≥ 1.0 × 109/l 10.6 3.09 (1.52-6.32) 0.002 11.9 4.02 (1.80-8.97) 0.001
   < 1.0 × 109/l 4.0    2.9   
  1. LDH, lactate dehydrogenase; IPI, International Prognostic Index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; PIT, Prognostic Index for peripheral T-cell lymphoma; ALC, absolute lymphocyte count; OS, overall survival; PFS, progression free survival.